Stay updated on DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Sign up to get notified when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.

Latest updates to the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page
- Check5 days agoChange DetectedAdded related topics: Type 2 diabetes and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoChange DetectedThe page content remains consistent with no significant changes to essential study information; only minor UI layout differences are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check19 days agoChange DetectedThe 'Type 2 diabetes' condition label and related topics (MedlinePlus Genetics) were removed from the page.SummaryDifference0.1%

- Check26 days agoChange DetectedRemoved the MedlinePlus Genetics topic on Type 2 diabetes, narrowing the genetics topics covered on the page.SummaryDifference0.3%

- Check40 days agoChange Detected- Updated version from v3.1.0 to v3.2.0 and added a government operation status notice and a new MedlinePlus Genetics topic on Type 2 diabetes. The previous v3.1.0 reference was removed.SummaryDifference4%

- Check48 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.